TREVENTIS

10 articles about TREVENTIS

• Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda

  4/11/2023

  Treventis Corporation, a privately held biotechnology company, announced today that it has entered an option, collaboration, and license agreement with Takeda for the further research, development, and commercialization of small molecules that target tau, a key protein in Alzheimer's Disease (AD).

• Treventis Awarded $2.97M Grant from the U.S. Department of Defense

  10/18/2022

  Treventis Corporation, a privately held biotechnology company, announced that their proposal to preclinically develop a small molecule anti-tau misfolding drug has been awarded funding totaling $2,977,166 by the Congressionally Directed Medical Research Programs, part of the DOD.

• 

  Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  9/23/2019

  50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.

• Servier and Treventis Begin Strategic Research Partnership in Neurodegenerative Diseases

  1/4/2018

  This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism.

• TREVENTIS Pre Clinical Candidate TRV 101 Demonstrates Significant Reduction In Both Amyloid Beta And Tau Toxic Aggregates In Animal Models Of Alzheimer's Disease

  7/20/2015

• TREVENTIS Closes $4.4 Million Financing With Wellcome Trust

  9/20/2013

• TREVENTIS Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimer's Disease Research, His Third Endowed Chair

  7/11/2012

• TREVENTIS Founder Wins Prestigious Discovery Award

  1/12/2011

• TREVENTIS Scientific Founder Donald Weaver, MD, Named 2009 Recipient of Prix Galien Canada Award for Outstanding Achievement in Development of New Medicines for Alzheimer's Disease

  12/16/2009

• BioAdvance Funds TREVENTIS to Advance Alzheimer's Drug Discovery

  8/10/2009